🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

5,609 results for “AB” Clear

  1. HW071021 Tablets

    Wuhan Humanwell Innovative Drug Research and Development Center Limited Company

    Advanced Solid Tumors

    phase 1 small molecule active

    1 trial

  2. HW071021 Tablets

    BRIGHT MINDS BIOSCIENCES INC.

    Advanced Solid Tumors

    phase 1 small molecule active

    1 trial

  3. Hemay005 tablet

    Anhui Hemay Pharmaceutical Co., Ltd

    Chronic Obstructive Pulmonary Disease

    phase 1 small molecule completed

    1 trial

  4. Hero: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of ION269 in Participants With Down Syndrome (DS) at Risk for Alzheimer’s Disease (AD)

    IONIS PHARMACEUTICALS INC

    Alzheimer’s Disease in Individuals with Down Syndrome

    phase 1 other active

    1 trial

  5. Huafu Shengji Ointment

    Universal Integrated

    Diabetic Foot

    phase 1 small molecule active

    1 trial

  6. Humalog

    HALOZYME THERAPEUTICS, INC.

    Diabetes Mellitus

    phase 1 small molecule completed

    1 trial

  7. Hydrocodone Bitartrate extended-release tablet

    Teva Pharma GmbH

    Renal Impairment

    phase 1 small molecule completed

    1 trial

  8. Hydrocodone bitartrate extended-release tablet

    Teva Pharma GmbH

    Hepatic Impairment

    phase 1 small molecule completed

    1 trial

  9. INZ-701, INZ-701

    Lacuna Pharma Pty Ltd

    Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency or ATP-binding Cassette Sub-family C Member 6 (ABCC6) Deficiency

    phase 1 small molecule active

    1 trial

  10. ISIS 325568

    IONIS PHARMACEUTICALS INC

    Type 2 Diabetes Mellitus

    phase 1 small molecule completed

    1 trial

  11. ISIS 388626

    IONIS PHARMACEUTICALS INC

    Type 2 Diabetes Mellitus

    phase 1 small molecule completed

    1 trial

  12. Imaging procedure to measure the distribution of a newly developed radiolabeled ligand for the oxytocin receptor

    Tonix Pharmaceuticals Holding

    Pain, Face

    phase 1 small molecule completed

    1 trial

  13. Impact of CardiolRxTM on Recurrent Pericarditis: An open label Pilot Study

    Cardiol Therapeutics

    Recurrent Pericarditis

    phase 1 other active

    1 trial

  14. Indacaterol (QAB149)

    Novartis Pharmaceuticals

    Healthy

    phase 1 small molecule completed

    1 trial

  15. Insulin Lispro

    HALOZYME THERAPEUTICS, INC.

    Diabetes Mellitus

    phase 1 small molecule completed

    1 trial

  16. Insulin aspart

    HALOZYME THERAPEUTICS, INC.

    Type 1 Diabetes Mellitus

    phase 1 small molecule completed

    1 trial

  17. Insulin degludec injection, RD15003

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Type 2 Diabetes

    phase 1 mab completed

    1 trial

  18. Interventional, open-label, single-group, long-term follow-up trial of Lu AG22515 in patients with moderate-to-severe Thyroid Eye Disease

    H. Lundbeck A/S

    Active, moderate-to-severe TED

    phase 1 other active

    1 trial

  19. Intralesional Cemiplimab for Adult Patients with Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma

    Lacuna Pharma Pty Ltd

    Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma

    phase 1 other active

    1 trial

  20. Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participants

    Lacuna Pharma Pty Ltd

    Geographic Atrophy

    phase 1 other active

    1 trial

  21. Investigating how CagriSema, semaglutide and cagrilintide regulate insulin effects in the body of people with type 2 diabetes.

    NovoThirteen

    Type 2 diabetes

    phase 1 other active

    1 trial

  22. Investigating how NNC0487-0111 regulates insulin in adults with type 2 diabetes

    NovoThirteen

    Type 2 Diabetes

    phase 1 other active

    1 trial

  23. Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Subcutaneous Injections of NNC0582-0001 in Healthy Adults

    NovoThirteen

    Healthy Volunteers

    phase 1 other active

    1 trial

  24. Investigation of pharmacokinetics, safety and tolerability of a single subcutaneous dose of NNC0487-0111 in participants with various degrees of renal impairment and normal renal function.

    NovoThirteen

    Obesity and Diabetes mellitus Typ 2

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources